U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07332000) titled 'A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec' on Dec. 17, 2025.
Brief Summary: Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, favorable intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer Patients Treated by Radiotherapy
Intervention:
BIOLOGICAL: aglatimagene besadenovec + valacyclovir
This is an open-label, single-group study in which up to 30...